Brett Monia, Ionis Pharmaceuticals CEO
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
A few days after Bayer ended its collaboration with Ionis, the biotech is trudging forward with another program it sold to Roche over the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
